Welcome to our dedicated page for Humana SEC filings (Ticker: HUM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Humana Inc. filings document formal disclosures for a public healthcare company with Humana insurance services and CenterWell healthcare services. Recent 8-K reports cover quarterly results, GAAP and non-GAAP earnings measures, Insurance segment benefit ratio commentary, Medicare Advantage membership assumptions, Regulation FD communications, and guidance updates.
Humana's SEC records also include proxy and annual-meeting materials covering director elections, auditor ratification, stockholder voting results, board composition, and director compensation program disclosures; board and executive transition disclosures; and capital-structure filings for registered debt offerings, including junior subordinated notes described through Form S-3 and prospectus-supplement materials.
Humana Inc. executive Aaron Martin, President of Medicare Advantage, filed an initial insider ownership report as of 01/26/2026. The filing shows he beneficially owns 0 shares of Humana common stock, held directly. No derivative securities such as options or warrants are listed as beneficially owned. This is an administrative disclosure of his current holdings as a company officer.
Humana Inc. President & CEO James A. Rechtin reported routine equity award activity on January 8, 2026. A total of 2,183 restricted stock units converted into the same number of Humana common shares at $0 per share under the company’s 2019 Amended & Restated Stock Incentive Plan.
Of these shares, 980 Humana common shares were withheld at a price of $279.1475 per share to satisfy tax obligations related to vesting, with no value received in return. Following these transactions, 28,305 Humana common shares were beneficially owned indirectly through two revocable trusts for the benefit of Rechtin and his spouse, where they serve as sole trustees.
Rechtin also holds stock options covering 29,230 Humana shares at an exercise price of $458.185 and options covering 15,772 shares at $367.21, as well as 14,054 restricted stock units, all granted under the same incentive plan with multi-year vesting schedules.
Humana Inc. director David T. Feinberg reported equity transactions in company stock and stock units. On 01/02/2026, he acquired 766 shares of Humana common stock at a reported price of $0, increasing his directly held beneficial ownership to 1,207 shares.
The filing also details changes in his deferred restricted stock units (RSUs). An existing block of 1,593 RSUs remains outstanding, each representing the right to receive one share of Humana common stock. On 12/31/2025, he elected to convert a director cash fee into 70 stock units and reinvest a dividend into 29 stock units, both deferred and valued at $258.8675 per unit, bringing their respective RSU balances to 708 and 46 units. All units are payable in Humana common stock on a 1-for-1 basis under the company’s equity plan and are reported as exempt under Rule 16b-3.
Humana Inc. director Wayne A. I. Frederick reported equity transactions in Humana common stock. The filing shows a disposition of 440 shares of Humana common stock in Table I.
In Table II, he acquired 766 restricted stock units on 01/02/2026 and 35 restricted stock units on 12/31/2025, each tied to Humana common stock. Following these transactions, he directly beneficially owned 3,174 restricted stock units from the first line and 73 from the second.
According to the footnotes, the larger grant represents an annual director’s fee payable in stock units under Humana’s 2019 Amended & Restated Plan, while the smaller amount reflects dividends reinvested into stock units. Both types of units are deferred until he resigns as a director, when they will be settled in Humana common stock on a one-for-one basis.
Humana Inc. director John W. Garratt reported equity awards and his updated holdings. On 12/31/2025, he acquired 16 restricted stock units tied to dividend payments, and on 01/02/2026 he acquired 766 restricted stock units as part of his annual director fee. These stock units are deferred until he resigns as a director, when they will be settled in Humana common stock on a 1-for-1 basis under the company’s 2019 Amended & Restated Plan.
Following these transactions, he directly beneficially owns 1,685 shares of Humana common stock. He also beneficially owns 1,929 restricted stock units described in note (1) and 18 restricted stock units described in note (2) as derivative securities, each corresponding to one share of Humana common stock upon settlement.
Humana Inc. director reports equity transactions and updated holdings. Director Marcy S. Klevorn reported activity in Humana common stock and related stock units. The filing shows a disposition of 436 shares of Humana common stock in the non-derivative section. In the derivative section, she acquired 766 restricted stock units as part of her annual director’s fee, which is payable in stock units deferred until her resignation, and 28 additional stock units from a director’s dividend payment reinvested at a price of $258.8675 per unit. Following these transactions, she beneficially owns 2,771 restricted stock units tied to Humana common stock under one award and 53 units under the dividend reinvestment award, each representing a contingent right to receive one share of Humana common stock on a 1-for-1 basis.
Humana Inc. director Frank A. D'Amelio reported new and existing equity holdings in the company. On 01/02/2026, he acquired 766 restricted stock units, which represent a contingent right to receive Humana common stock under the company’s 2019 Amended & Restated Plan. These units, along with other deferred stock units, are generally payable in Humana common stock on a 1-for-1 basis after his resignation as a director.
The filing shows a total of 26,826 restricted stock units held directly after the reported transaction, plus additional deferred stock units from converting director cash fees (2,467 units) and reinvested dividends (318 units). It also notes 20,634 Humana common shares held indirectly in a 2024 Grantor Retained Annuity Trust for which he serves as sole trustee.
Humana Inc. director Jorge S. Mesquita reported receiving 766 restricted stock units of Humana common stock on 01/02/2026. These units represent a contingent right to receive one share of Humana common stock for each unit and are noted as exempt under Rule 16b-3(d)(1)&(3) pursuant to the company's 2019 Amended & Restated Plan.
Following this grant, a total of 4,127 Humana shares, including the 766 restricted stock units, are reported as beneficially owned indirectly through a revocable trust where Mesquita is the sole trustee.
Humana Inc. director Kurt J. Hilzinger reported routine equity compensation activity. On 12/31/2025, he acquired restricted stock units tied to his director compensation and dividend reinvestment, including 611 units from reinvested dividends and 357 units from electing to convert cash fees into stock units at a price of $258.8675 per unit. On 01/02/2026, he received an additional 766 restricted stock units as part of his annual director fee, all payable in Humana common stock on a 1-for-1 basis after his board service ends.
Following these transactions, Hilzinger directly beneficially owns 19,448 Humana common shares and holds multiple blocks of deferred restricted stock units, including 24,800 units in one plan-based award. These awards are reported as exempt under Rule 16b-3 and reflect compensation elections rather than open-market buying or selling.
Humana Inc. director Karen W. Katz reported changes in her equity holdings. The filing shows a disposition of 590 shares of Humana common stock. She also reported derivative holdings in the form of restricted stock units (RSUs).
On 01/02/2026, Katz acquired 766 RSUs, which are part of her annual director’s fee payable in stock units and deferred until her resignation, when they will convert into Humana common stock on a one-for-one basis. On 12/31/2025, she acquired an additional 49 RSUs, related to dividend reinvestment on vested and deferred stock units at a price of $258.8675 per underlying share. Some director cash fees were also elected to be converted into deferred stock units, all payable in Humana common stock on a one-for-one basis upon her resignation.